[go: up one dir, main page]

MXPA03010655A - Gel oft??lmico de pirenzepina. - Google Patents

Gel oft??lmico de pirenzepina.

Info

Publication number
MXPA03010655A
MXPA03010655A MXPA03010655A MXPA03010655A MXPA03010655A MX PA03010655 A MXPA03010655 A MX PA03010655A MX PA03010655 A MXPA03010655 A MX PA03010655A MX PA03010655 A MXPA03010655 A MX PA03010655A MX PA03010655 A MXPA03010655 A MX PA03010655A
Authority
MX
Mexico
Prior art keywords
ophthalmic gel
pirenzepine
pirenzepine ophthalmic
gel
pharmaceutically acceptable
Prior art date
Application number
MXPA03010655A
Other languages
English (en)
Inventor
Harun Takruri
Original Assignee
Valley Forge Pharmaceuticals I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valley Forge Pharmaceuticals I filed Critical Valley Forge Pharmaceuticals I
Publication of MXPA03010655A publication Critical patent/MXPA03010655A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Es un objeto primario de la presente invencion proporcionar una formulacion oftalmica acuosa, para tratar la miopia, esta formulacion comprende la pirenzepina en combinacion con un portador de gel, aceptable farmaceuticamente.
MXPA03010655A 2001-05-25 2002-05-01 Gel oft??lmico de pirenzepina. MXPA03010655A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29373101P 2001-05-25 2001-05-25
PCT/US2002/013823 WO2002096418A1 (en) 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel

Publications (1)

Publication Number Publication Date
MXPA03010655A true MXPA03010655A (es) 2007-06-22

Family

ID=23130330

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010655A MXPA03010655A (es) 2001-05-25 2002-05-01 Gel oft??lmico de pirenzepina.

Country Status (17)

Country Link
US (2) US20040137069A1 (es)
EP (1) EP1397132A4 (es)
JP (1) JP2004531569A (es)
KR (1) KR20040018380A (es)
CN (1) CN1509172A (es)
BR (1) BR0210013A (es)
CA (1) CA2447562A1 (es)
EC (1) ECSP044862A (es)
HU (1) HUP0304071A2 (es)
IL (1) IL158904A0 (es)
MX (1) MXPA03010655A (es)
NO (1) NO20035224D0 (es)
NZ (1) NZ529615A (es)
PL (1) PL366924A1 (es)
RU (1) RU2297831C2 (es)
WO (1) WO2002096418A1 (es)
ZA (1) ZA200309791B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2573673A1 (en) 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
JP4963359B2 (ja) * 2005-01-12 2012-06-27 ロート製薬株式会社 眼局所適用製剤
BRPI0709663A2 (pt) 2006-03-31 2011-07-26 Qlt Plug Delivery Inc mÉtodos de liberaÇço de drogas, estruturas e composiÇÕes para um sistema nasolacrimal
CA2674076A1 (en) * 2006-12-26 2008-07-10 Qlt Plug Delivery, Inc. Drug delivery implants for inhibition of optical defects
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
BRPI0817075A2 (pt) 2007-09-07 2016-07-26 Qlt Plug Delivery Inc núcleos de fármaco para liberação prolongada de agentes terapêuticos
WO2010083129A2 (en) 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
DK2632468T3 (en) 2010-10-25 2018-02-12 Univ Manitoba THERAPEUTIC COMPOSITIONS FOR SYMMETRIC DIABETIC POLYNEuropathy
HRP20191711T1 (hr) * 2011-03-14 2019-12-13 Drug Delivery Solutions Ltd Oftalmološki pripravak
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
CN105663137A (zh) * 2016-01-14 2016-06-15 王真 哌仑西平在制备治疗脓毒症疾病的药物中的应用
SG11201809822SA (en) * 2016-05-25 2018-12-28 Singapore Health Serv Pte Ltd Atropine-containing aqueous composition
WO2019087146A1 (en) 2017-11-03 2019-05-09 Novartis Ag Azabicyclo and diazepine derivatives for treating ocular disorders
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
JP7407462B2 (ja) * 2019-03-26 2024-01-04 ウィンサンター・インコーポレイテッド 末梢神経障害の処置のための局所製剤
CA3142885A1 (en) * 2019-06-10 2020-12-17 Jenivision Inc. Methods and formulations for treating vision disorders
WO2021007578A1 (en) * 2019-07-11 2021-01-14 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods
KR102808906B1 (ko) * 2021-06-18 2025-05-19 대우제약 주식회사 고점도 점안제를 무균여과하는 방법
CN117338787A (zh) * 2023-11-24 2024-01-05 南京恒道医药科技股份有限公司 一种眼用药物组合物及其制备方法
WO2025171327A1 (en) * 2024-02-09 2025-08-14 Levation Pharma Ltd. Methods for producing dermatological gel compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
JP3165436B2 (ja) * 1989-06-21 2001-05-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 眼の発達の治療及び制御
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
SU1827797A3 (ru) * 1991-04-30 1996-05-20 Н.Б. Леонидов Лекарственный препарат для анестезии глаз
US5461808A (en) * 1993-02-08 1995-10-31 Fritts; Robert W. Table top backlit display
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5461052A (en) * 1993-04-30 1995-10-24 The Trustees Of The University Of Pennsylvania Prevention of myopia by tricyclic compounds
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
RU2135129C1 (ru) * 1998-11-18 1999-08-27 Ларионов Евгений Викторович Глазные капли "корнеалон-плюс"
US6164282A (en) * 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia

Also Published As

Publication number Publication date
RU2003136735A (ru) 2005-03-27
RU2297831C2 (ru) 2007-04-27
NO20035224D0 (no) 2003-11-24
EP1397132A1 (en) 2004-03-17
ZA200309791B (en) 2004-10-04
WO2002096418A1 (en) 2002-12-05
CA2447562A1 (en) 2002-12-05
CN1509172A (zh) 2004-06-30
BR0210013A (pt) 2004-08-10
PL366924A1 (en) 2005-02-07
US20040137069A1 (en) 2004-07-15
ECSP044862A (es) 2004-03-23
US20060188576A1 (en) 2006-08-24
NZ529615A (en) 2005-07-29
EP1397132A4 (en) 2006-12-13
HUP0304071A2 (hu) 2004-04-28
IL158904A0 (en) 2004-05-12
KR20040018380A (ko) 2004-03-03
JP2004531569A (ja) 2004-10-14

Similar Documents

Publication Publication Date Title
MXPA03010655A (es) Gel oft??lmico de pirenzepina.
AU3831301A (en) Method for treating ocular pain
CA97146S (en) Eyeglasses
CA97145S (en) Eyeglasses
MY137757A (en) Therapeutic treatment
IT1333697B (es)
MY135233A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
MY127290A (en) New use of flibanserin
MXPA03007140A (es) Derivados de carbolina.
SI1496912T1 (sl) Kombinacija brimonidina in timolola za topikalno oftalmološko uporabo
SG146442A1 (en) Sulphonamide derivatives, their preparation and use as medicaments
DE60216233D1 (en) Carbolinderivate
CY1106409T1 (el) Παραγωγα κινολινης
HK1046631A1 (zh) 含有酮替芬的眼药组合物
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
WO2003028628A3 (en) Photosensitizing carbamate derivatives
AU2003219046A1 (en) Cationic polymers and the use thereof in cosmetic formulations
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
SI1463563T1 (sl) Superoksidni dizmutazni mimetiki za zdravljenje očesnih motenj in bolezni
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
AU2002365288A1 (en) Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
WO2003045428A3 (de) Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
EP1436279A4 (en) CHEMICAL COMPOUNDS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal